## **Resource Summary Report**

Generated by FDI Lab - SciCrunch.org on May 18, 2025

# APC anti-human/mouse Granzyme B Recombinant

RRID:AB\_2687028 Type: Antibody

#### **Proper Citation**

(BioLegend Cat# 372204, RRID:AB\_2687028)

#### Antibody Information

URL: http://antibodyregistry.org/AB\_2687028

Proper Citation: (BioLegend Cat# 372204, RRID:AB\_2687028)

Target Antigen: Granzyme B

Host Organism: mouse

Clonality: recombinant monoclonal

Comments: Applications: ICFC

Antibody Name: APC anti-human/mouse Granzyme B Recombinant

Description: This recombinant monoclonal targets Granzyme B

Target Organism: Human, Mouse

Clone ID: Clone QA16A02

Antibody ID: AB\_2687028

Vendor: BioLegend

Catalog Number: 372204

Alternative Catalog Numbers: 372203

**Record Creation Time:** 20231110T034045+0000

Record Last Update: 20240725T063202+0000

#### **Ratings and Alerts**

No rating or validation information has been found for APC anti-human/mouse Granzyme B Recombinant.

No alerts have been found for APC anti-human/mouse Granzyme B Recombinant.

### Data and Source Information

Source: Antibody Registry

#### **Usage and Citation Metrics**

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Cao T, et al. (2024) Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8+ T cells. Cell, 187(9), 2288.

Lane IC, et al. (2024) Genetic retargeting of E3 ligases to enhance CAR T cell therapy. Cell chemical biology, 31(2), 338.

Wang S, et al. (2024) Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR Mutant Non-Small Cell Lung Cancer. Cancer research.

Hu Y, et al. (2024) Selective refueling of CAR T cells using ADA1 and CD26 boosts antitumor immunity. Cell reports. Medicine, 5(5), 101530.

Zhang Y, et al. (2023) CD39 inhibition and VISTA blockade may overcome radiotherapy resistance by targeting exhausted CD8+ T cells and immunosuppressive myeloid cells. Cell reports. Medicine, 4(8), 101151.

Lin YH, et al. (2023) Small intestine and colon tissue-resident memory CD8+ T cells exhibit molecular heterogeneity and differential dependence on Eomes. Immunity, 56(1), 207.

Ma L, et al. (2023) Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell, 186(15), 3148.

Yan H, et al. (2023) The transcription factor IRF4 determines the anti-tumor immunity of CD8+ T cells. iScience, 26(11), 108087.

Yi J, et al. (2023) Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy. Nature communications, 14(1), 1941.

Brown H, et al. (2023) Lymph node sharing between pancreas, gut, and liver leads to immune crosstalk and regulation of pancreatic autoimmunity. Immunity, 56(9), 2070.

Li YR, et al. (2023) Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design. iScience, 26(10), 107952.

O'Donnell KL, et al. (2023) Rapid protection of nonhuman primates against Marburg virus disease using a single low-dose VSV-based vaccine. EBioMedicine, 89, 104463.

Liu Y, et al. (2023) PD-L1-mediated immune evasion in triple-negative breast cancer is linked to the loss of ZNF652. Cell reports, 42(11), 113343.

Thumkeo D, et al. (2022) PGE2-EP2/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment. Cell reports, 39(10), 110914.

Li YR, et al. (2022) Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers. iScience, 25(9), 104859.

Li YR, et al. (2021) Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Cell reports. Medicine, 2(11), 100449.

Wang C, et al. (2021) Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade. Cell reports, 37(8), 110021.

Ng KW, et al. (2019) Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist. eLife, 8.

Zhu Y, et al. (2019) Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. Cell stem cell, 25(4), 542.

Lu Y, et al. (2018) Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors. Cancer cell, 33(6), 1048.